Merus Labs International

MSL-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about MSL-T

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
June 8, 2016

(A Top Pick June 12/15. Down 50.15%.) This got caught up in the healthcare problems. The sentiment around the sector has been very, very bad. The underlying performance is still quite good. He likes the prospects.

Show full opinionHide full opinion

(A Top Pick June 12/15. Down 50.15%.) This got caught up in the healthcare problems. The sentiment around the sector has been very, very bad. The underlying performance is still quite good. He likes the prospects.

DON'T BUY
DON'T BUY
May 24, 2016

Trying to focus on European markets which they feel is less prone to regulation as each jurisdiction in Europe is regulated separately. Have done a number of acquisitions. However, some of the drugs in their pipeline have a declining profile, so you have to be really careful to understand how their base business is doing and how much they are paying for acquisitions. It is hard to gauge whether they have overpaid are not for the right acquisitions, but he doesn’t feel they got them cheap. Also, they have utilized the stock price to pay for some of those. Be very careful on this one.

Show full opinionHide full opinion

Trying to focus on European markets which they feel is less prone to regulation as each jurisdiction in Europe is regulated separately. Have done a number of acquisitions. However, some of the drugs in their pipeline have a declining profile, so you have to be really careful to understand how their base business is doing and how much they are paying for acquisitions. It is hard to gauge whether they have overpaid are not for the right acquisitions, but he doesn’t feel they got them cheap. Also, they have utilized the stock price to pay for some of those. Be very careful on this one.

HOLD
HOLD
May 17, 2016

In the Canadian drug business. A bit smaller name, so probably doesn’t get the following that some of the larger names do. In his ranking, it is pretty much in the middle of the pack from a fundamental and technical standpoint. Just did an acquisition last year and he was a little surprised the stock price didn’t move up, but actually moved down. Thinks it was a function of the space in general and investors appetite for those kinds of stocks. Trades at a cheap valuation. If you are patient, it is probably a good time to Hold and you will see some capital appreciation as they continue to build out their brands and also get a little more recognition from the market for what they have and what they have purchased recently, which they got at a pretty cheap multiple.

Show full opinionHide full opinion

In the Canadian drug business. A bit smaller name, so probably doesn’t get the following that some of the larger names do. In his ranking, it is pretty much in the middle of the pack from a fundamental and technical standpoint. Just did an acquisition last year and he was a little surprised the stock price didn’t move up, but actually moved down. Thinks it was a function of the space in general and investors appetite for those kinds of stocks. Trades at a cheap valuation. If you are patient, it is probably a good time to Hold and you will see some capital appreciation as they continue to build out their brands and also get a little more recognition from the market for what they have and what they have purchased recently, which they got at a pretty cheap multiple.

COMMENT
COMMENT
April 21, 2016

A small-cap Canadian specialty pharma company. He likes management, but this has taken on more leverage than they should have. Would like to see an equity issue out of the company in order to de-lever the balance sheet a bit more.

Show full opinionHide full opinion

A small-cap Canadian specialty pharma company. He likes management, but this has taken on more leverage than they should have. Would like to see an equity issue out of the company in order to de-lever the balance sheet a bit more.

BUY
BUY
April 11, 2016

In the specialty Pharma space, which has had a lot of troubles. Multiples have contracted quite a bit. Compared to their competitors, they have had a much cleaner balance sheet. Haven’t actually made their big acquisitions yet to load up the balance sheet with debt. They were able to raise about $30 million earlier this year. New management has executed well on the deals and their European jurisdiction. At this level, it is a pretty compelling Buy, but you have to be willing to ride out the volatility from headlines.

Show full opinionHide full opinion

In the specialty Pharma space, which has had a lot of troubles. Multiples have contracted quite a bit. Compared to their competitors, they have had a much cleaner balance sheet. Haven’t actually made their big acquisitions yet to load up the balance sheet with debt. They were able to raise about $30 million earlier this year. New management has executed well on the deals and their European jurisdiction. At this level, it is a pretty compelling Buy, but you have to be willing to ride out the volatility from headlines.

TOP PICK
TOP PICK
March 29, 2016

This owns a portfolio of drugs in Europe. Because the European market is already very highly regulated, they don’t have the same issues with pricing that others have. Very stable margins. They just raised $25 million at $1.90 through sub receipts. When that closes, they can be swapped for shares in the stock will go back to $1.90. There is the short term upside, but longer-term he loves the growth profile.

Show full opinionHide full opinion

This owns a portfolio of drugs in Europe. Because the European market is already very highly regulated, they don’t have the same issues with pricing that others have. Very stable margins. They just raised $25 million at $1.90 through sub receipts. When that closes, they can be swapped for shares in the stock will go back to $1.90. There is the short term upside, but longer-term he loves the growth profile.

HOLD
HOLD
March 7, 2016

A good little pharmaceutical company. Have done a lot of acquisitions. One concern is that over the last 4 years they keep growing, but we are not getting anything much happening on a per share basis. A lot of the CEO’s compensation is built around the size of the company, not on a per share basis, so if he doubles the size of the company he doubles his salary. Jason has 1 foot in the door and 1 foot out on this company.

Show full opinionHide full opinion

A good little pharmaceutical company. Have done a lot of acquisitions. One concern is that over the last 4 years they keep growing, but we are not getting anything much happening on a per share basis. A lot of the CEO’s compensation is built around the size of the company, not on a per share basis, so if he doubles the size of the company he doubles his salary. Jason has 1 foot in the door and 1 foot out on this company.

COMMENT
COMMENT
February 24, 2016

Has been kind of beaten up over the last year as people were really waiting for them to make some sort of acquisition. Recently did 2 and raised some money. As the market becomes more comfortable with this, you’ll start to see the stock value a little better over time. Prefers Concordia Healthcare (CXR-T).

Show full opinionHide full opinion

Has been kind of beaten up over the last year as people were really waiting for them to make some sort of acquisition. Recently did 2 and raised some money. As the market becomes more comfortable with this, you’ll start to see the stock value a little better over time. Prefers Concordia Healthcare (CXR-T).

HOLD
HOLD
February 23, 2016

Another health care company that has been a wild, wild ride. Looked really interesting because they were in the early innings of an active growth by acquisition story. They buy high free cash flowing businesses that are going to be good down the road, in order to de-lever the balance sheet so that they can make more acquisitions. Thinks they are in the early stages of this, and the stock is worth a lot more than what it is trading at now. A good long term hold.

Show full opinionHide full opinion

Another health care company that has been a wild, wild ride. Looked really interesting because they were in the early innings of an active growth by acquisition story. They buy high free cash flowing businesses that are going to be good down the road, in order to de-lever the balance sheet so that they can make more acquisitions. Thinks they are in the early stages of this, and the stock is worth a lot more than what it is trading at now. A good long term hold.

WATCH
WATCH
January 25, 2016

Technically it looks okay. It is in a growth channel. It has been building a base. He wants to see more volume before entering it.

Show full opinionHide full opinion

Technically it looks okay. It is in a growth channel. It has been building a base. He wants to see more volume before entering it.

COMMENT
COMMENT
January 13, 2016

Has owned this in the past. Probably one of the cheaper Canadian companies in its category. It shows up on his radar screen, but pretty much in the middle of the pack.

Show full opinionHide full opinion

Has owned this in the past. Probably one of the cheaper Canadian companies in its category. It shows up on his radar screen, but pretty much in the middle of the pack.

COMMENT
COMMENT
January 8, 2016

Has a much better balance sheet than Concordia Healthcare (CXR-T). Raised money at higher prices, so they have cash on the balance sheet, so you don’t worry about the debt level. Cash flows and multiples are also much lower than Concordia. He is waiting for them to redeploy that capital and thinks they are going to make an acquisition fairly soon. The stock should react positively.

Show full opinionHide full opinion

Has a much better balance sheet than Concordia Healthcare (CXR-T). Raised money at higher prices, so they have cash on the balance sheet, so you don’t worry about the debt level. Cash flows and multiples are also much lower than Concordia. He is waiting for them to redeploy that capital and thinks they are going to make an acquisition fairly soon. The stock should react positively.

HOLD
HOLD
January 6, 2016

(Market Call Minute.) He would consider it as a Hold. Prefers Concordia (CXR-T).

Show full opinionHide full opinion

(Market Call Minute.) He would consider it as a Hold. Prefers Concordia (CXR-T).

WEAK BUY
WEAK BUY
January 4, 2016

A company like VRX-T. They have no US exposure, which looks good. MRK-N would be his favourite in this space.

Show full opinionHide full opinion

A company like VRX-T. They have no US exposure, which looks good. MRK-N would be his favourite in this space.

COMMENT
COMMENT
December 23, 2015

This is his preference in healthcare. On value versus growth, this is really a deep value kind of stock. Was trading at $3 not long ago, and thinks it could easily get back to that over the next year. Trading at about 4.5 or 5 times EBITDA.

Show full opinionHide full opinion

This is his preference in healthcare. On value versus growth, this is really a deep value kind of stock. Was trading at $3 not long ago, and thinks it could easily get back to that over the next year. Trading at about 4.5 or 5 times EBITDA.

Showing 16 to 30 of 68 entries